Risperidone [106266-06-2]

Kamińska K, Gołembiowska K, Rogóż Z. Effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. Pharmacol Rep. 2013;65(5):1144-51. PMID: 24399710. MacDowell KS, García-Bueno B, Madrigal JL, et al. Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int J Neuropsychopharmacol. 2013 Feb;16(1):121-35. PMID: 22176740. Kozielska M, Johnson M, Pilla Reddy V, et al. Pharmacokinetic-pharmacodynamic modeling of the D2 and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res. 2012 Jul;29(7):1932-48. PMID: 22437487. Abou El-Magd RM, Park HK, Kawazoe T, et al. The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia. J Psychopharmacol. 2010 Jul;24(7):1055-67. PMID: 19329549. Toohey N, Klein MT, Knight J, et al. Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other "inactivating antagonists". Mol Pharmacol. 2009 Sep;76(3):552-9. PMID: 19509219. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003 Jul;60(7):681-90. PMID: 12860772. Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):19S-23S. PMID: 7537284.